We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Pfizer vaccine: How I’m investing now

Pfizer’s coronavirus vaccine has been described as a ‘game-changer’ for stocks. Here, Motley Fool writer Edward Sheldon looks at where he is investing now.

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

News that pharmaceutical giant Pfizer has developed a coronavirus vaccine sent UK shares higher this week. This vaccine has been described as a ‘game-changer’ for stocks. As a result, investors have been scrambling to reposition their portfolios. 

Here, I’m going to look at where I’m investing my own money now that a coronavirus vaccine is on the horizon. These are the stocks I’m buying.

Should you buy Rolls Royce shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Pfizer vaccine: a game-changer? 

On the back of the vaccine news, many investors are now piling into the sectors that were hit the hardest by Covid-19, such as airlines, oil, and hospitality. However, this is not an approach I’m going to take. A vaccine will certainly benefit companies in these industries. Yet many may continue to face challenges for a while.

Airlines, for example, may not return to normal for years, despite a vaccine. The coronavirus has devastated this industry, and demand may be depressed for years. Aviation analyst John Strickland summed up the situation well. He responded to the vaccine development by saying: “This news is certainly very welcome but it would be massively premature to say that the airline sector can now return to normal. Enormous damage has already been done and we can expect failures this winter”.

Where I’m investing now

So, where will I be investing now that a vaccine is on the cards? Well, in recent years, I’ve been focusing my portfolio on three main types of stocks. I plan to continue investing this way going forward.

Large-cap technology stocks are one area of the stock market I’ve been focusing on. Companies I’ve invested in include Microsoft, Amazon, and Mastercard. In my view, all of these companies are well placed to benefit from the digital revolution. Amazon, for example, is benefiting from the growth of online shopping. Mastercard is benefiting from the shift to digital payments. Microsoft is benefiting from the growth of the cloud. I think these kinds of stocks should do well in the years ahead irrespective of what happens with Covid-19.

Large-cap dividend stocks are another area of the market I’ve focused on. Some examples of companies I’ve invested in include Diageo, Reckitt Benckiser, Unilever, and Smith & Nephew. All of these stocks have solid long-term growth potential. However, they’re a little less volatile than my growth stocks which means they bring stability to my portfolio. 

Finally, I’ve also invested a little bit of money in small-cap growth stocks. These kinds of stocks are higher risk. However, they have the potential for explosive gains. Some examples of stocks I’ve bought include dotDigitalKeywords Studios, and freelance employment platform operator Upwork.

My goal: strong long-term returns

All of the companies I am investing in are exposed to powerful growth themes such as increased digitalisation, the ageing population, and the rise of wealth in the emerging markets. This means they should grow significantly over time. All have competitive advantages which should protect market share.

Meanwhile, with the exception of a few of the smaller companies I own, most companies are highly profitable. This increases the chances that they will turn out to be good long-term investments.

I believe this focus on highly-profitable companies with strong growth prospects should deliver strong returns in the long run.

Edward Sheldon owns shares in Amazon, Microsoft, Mastercard, Reckitt Bencksiser, Unilever, Diageo, Smith & Nephew, Upwork, Keywords Studios and dotDigital. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool UK owns shares of and has recommended Amazon, Mastercard, and Microsoft. The Motley Fool UK has recommended Diageo, dotDigital Group, Keywords Studios, and Unilever and recommends the following options: long January 2021 $85 calls on Microsoft, short January 2021 $115 calls on Microsoft, short January 2022 $1940 calls on Amazon, and long January 2022 $1920 calls on Amazon. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Jumbo jet preparing to take off on a runway at sunset
Investing Articles

Rolls-Royce vs SpaceX: which aerospace giant is dominating the stock market in 2026?

SpaceX may be dominating headlines for now, but is it a better long-term option than one of the UK stock…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Lloyds shares seem unstoppable — but what do investors need to watch out for?

Lloyds' shares seem to be on an unstoppable march back to their former glory. But what do investors need to…

Read more »

Landlady greets regular at real ale pub
Investing Articles

By 2028, the dividends from Diageo shares could recover to…

Diageo shares saw their dividend slashed as a new turnaround strategy took shape. But could the payout already be on…

Read more »

Percy Pig Ocado van outside distribution centre
Investing Articles

By July 2027, the Ocado share price could go from 187p to…

With Ocado bagging new tech deals with the likes of Asda, is its bombed-out share price screaming opportunity to me…

Read more »

Overjoyed exited middle aged married couple giving high five, finishing doing domestic paperwork together at home. Euphoric happy older mature spouses celebrating successful investment or purchase.
Investing Articles

By 2030, the dividends from Legal & General shares could grow to…

With the highest yield in the FTSE 100 and a clear multi-year growth plan, could Legal & General shares be…

Read more »

Aviva logo on glass meeting room door
Investing Articles

9% yield? Here’s the dividend forecast for Aviva shares to 2030

Aviva shares already yield 5.8%. But according to long-term dividend forecasts, that could climb to nearly 9% within four years!…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Forget Rolls-Royce shares, this incredible penny stock is forecast to soar 762%!

Faron Pharmaceuticals shares are forecast to gain 762% in the coming 12 months, mimicking the recent performance of Rolls-Royce shares.

Read more »

Close-up of children holding a planet at the beach
Investing Articles

How to turn a £20,000 ISA into a £20-a-day passive income stream

Does earning regular passive income seem out of your grasp? Break it down to a simple, step-by-step plan, and it’s…

Read more »